Quick Takeaways
- CITADEL ADVISORS LLC filed SCHEDULE 13G for Allogene Therapeutics, Inc. Common Stock, par value $0.001 per share (the "Shares") (ALLO).
- Disclosed ownership: 6.1%.
- Date of event: 09 Jul 2025.
Quoteable Key Fact
"CITADEL ADVISORS LLC disclosed 6.1% ownership in Allogene Therapeutics, Inc. Common Stock, par value $0.001 per share (the "Shares") (ALLO) on 09 Jul 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Citadel Advisors LLC | 4.7% | 10,203,329 | 0 | 10,203,329 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Advisors Holdings LP | 4.7% | 10,203,329 | 0 | 10,203,329 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel GP LLC | 4.7% | 10,203,329 | 0 | 10,203,329 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Securities LLC | 1.4% | 3,142,822 | 0 | 3,142,822 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Securities Group LP | 1.4% | 3,142,822 | 0 | 3,142,822 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Securities GP LLC | 1.4% | 3,142,822 | 0 | 3,142,822 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Kenneth Griffin | 6.1% | 13,346,151 | 0 | 13,346,151 | /s/ Seth Levy | Seth Levy, attorney-in-fact* |